Trial Profile
Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Recurrent Survivin-Expressing Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs Maveropepimut-S (Primary) ; Cyclophosphamide
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors IMV
- 16 Jun 2021 Status changed from active, no longer recruiting to discontinued.
- 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
- 17 Jul 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.